Fig. 1
From: Correlating COVID-19 severity with biomarker profiles and patient prognosis
Biomarkers associated with the severity of COVID-19 during the convalescent phase. Plasma levels of biomarkers associated with participants with different clinical spectrums (n = 60 mild group, n = 65 moderate group, and n = 101 severe group). (a) Factor VIII, reference value 50–150%; (b) Von Willebrand factor, reference value 50–150%; (c) dimer D, reference value < 500 µg/L FEU; (d) Glycated hemoglobin, reference values: normoglycemia (< 5.7%), pre-diabetes or increased risk for DM (≥ 5.7% and < 6.5%), and DM (≥ 6.5%). Groups were compared using the Kruskal–Wallis test. If P < 0.05, paired comparisons were conducted with the Dunn-Bonferroni multiple comparison post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001.
